Amgen’s Pharma-Style Reorganization Includes Staff Cuts, Pipeline Prioritization
This article was originally published in Pharmaceutical Approvals Monthly
As Amgen enters into a major restructuring effort that will include extensive cost-cutting and significant headcount reductions, it will also make serious adjustments to its R&D program – including scaling back from its industry-leading approach of investing a high percentage of sales on R&D.
You may also be interested in...
Adiana uses a polymer matrix insert to block the fallopian tubes instead of a metal coil, offering a benefit over Essure, which carries a perforation risk on implantation, Hologic exec says.
The results show that cardiac resynchronization defibrillators "slow the progression of heart failure in asymptomatic and mildly symptomatic patients," potentially expanding the market by $600 million.
A little more than a week after an article published in The Lancet raised questions about the assumption that removing amyloid plaque is key to modifying Alzheimer's disease - an assumption upon which most drug makers are pinning their hopes - Wyeth, Lilly and Pfizer unveiled data on their respective agents at the International Conference on Alzheimer's Disease in Chicago